Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCYVDT)

Drug Name
Chlorzoxazone Drug Info
Synonyms
Biomioran; CLW; Chloroxazone; Chlorsoxazone; Chlorzoxane; Chlorzoxazon; Chlorzoxazona; Chlorzoxazonum; Clorzoxazona; Escoflex; Klorzoxazon; Mioran; Miotran; Myoflexin; Myoflexine; Neoflex; Nyoflex; Paraflex; Parafon; Pathorysin; Relaxazone; Remofleks; Remular; Solaxin; Component of Parafon Forte; McNeil Brand of Chlorzoxazone; Ortho Brand of Chlorzoxazone; Parafon Forte; Parafon Forte DSC; Strifon Forte Dsc; C 4397; Chlorzoxazonum [INN-Latin]; Clorzoxazona [INN-Spanish]; EZE-DS; Muscol (TN); Paraflex (TN); Parafon Forte (TN); Remular-S; Usaf ma-10; Chlorzoxazone [INN:BAN:JAN]; Chlorzoxazone (JAN/USP/INN); 2-Hydroxy-5-chlorobenzoxazole; 5-Chlorbenzoxazolin-2-on; 5-Chloro-1,3-benzoxazol-2(3H)-one; 5-Chloro-2(3H)-benzoxazolone; 5-Chloro-2-benzoxazolinone; 5-Chloro-2-benzoxazolol; 5-Chloro-2-benzoxazolone; 5-Chloro-2-hydroxybenzoxazole; 5-Chloro-3(H)-2-benzoxazolone; 5-Chlorobenzoksazolinon-2; 5-Chlorobenzoksazolinon-2 [Polish]; 5-Chlorobenzoksazolon-2; 5-Chlorobenzoksazolon-2 [Polish]; 5-Chlorobenzoxazol-2-one; 5-Chlorobenzoxazolidone; 5-Chlorobenzoxazolone; 5-chloro-1,3-benzoxazol-2-ol; 5-chloro-3H-1,3-benzoxazol-2-one; 5-chlorobenzoxazolin-2-one
Indication
Disease Entry ICD 11 Status REF
Acute pain MG31 Approved [1]
Therapeutic Class
Analgesics
Cross-matching ID
PubChem CID
2733
ChEBI ID
CHEBI:3655
CAS Number
CAS 95-25-0
TTD Drug ID
DMCYVDT
VARIDT Drug ID
DR00571
INTEDE Drug ID
DR0312
ACDINA Drug ID
D00127

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Calcium-activated potassium channel (KCN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Charybdotoxin DMKN345 Scorpion envenoming syndrome 8D43 Approved [12]
ICA-17043 DMRFY7I Alzheimer disease 8A20 Phase 2 [13]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one DMKMH5L Discovery agent N.A. Investigative [14]
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole DMQEJVU Conjunctival fibrosis 9A61.3 Investigative [14]
4-fluorophenyl-2,2-diphenylacetamide DMI03KV Discovery agent N.A. Investigative [13]
N-methyl-2,2,2-triphenylacetamide DMQGRMO Discovery agent N.A. Investigative [13]
TRIPHENYLMETHANAMINE DM3CQIZ Discovery agent N.A. Investigative [13]
N,N-dimethyl-2,2,2-triphenylacetamide DM9XZJN Discovery agent N.A. Investigative [13]
(2-fluorophenyl)-(4-fluorophenyl)phenylacetamide DMFV76H Discovery agent N.A. Investigative [13]
2,2,2-tris-(3-fluorophenyl)-acetamide DMJXAF7 Discovery agent N.A. Investigative [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [15]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [16]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [17]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [18]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [19]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [20]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [21]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [22]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [16]
Verapamil DMA7PEW Angina pectoris BA40 Approved [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [24]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [25]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [26]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [27]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [28]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [29]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [21]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [30]
Verapamil DMA7PEW Angina pectoris BA40 Approved [31]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2A6 (CYP2A6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [24]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [3]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [33]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [19]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [3]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [34]
Metronidazole DMTIVEN Abscess Approved [35]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [36]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [37]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [38]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [39]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [40]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [19]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [23]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [41]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [42]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [43]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [44]
Propranolol DM79NTF Angina pectoris BA40 Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2E1 (CYP2E1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Folic Acid DMEMBJC Colorectal carcinoma Approved [46]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [47]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [33]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [48]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [49]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [30]
Verapamil DMA7PEW Angina pectoris BA40 Approved [3]
Estrone DM5T6US Acne vulgaris ED80 Approved [50]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [51]
Ethanol DMDRQZU Chronic pain MG30 Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 102A1 (cyp102)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [8]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [53]
Propranolol DM79NTF Angina pectoris BA40 Approved [54]
Dextromethorphan DMUDJZM Allergic rhinitis CA08.0 Approved [8]
Nifedipine DMSVOZT Angina pectoris BA40 Approved [7]
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [8]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [8]
Mefenamic acid DMK7HFI Dysmenorrhea GA34.3 Approved [53]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [53]
GEA-6414 DM8J0MK N. A. N. A. Phase 1/2 [53]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Intermediate conductance calcium-activated potassium channel protein 4 (KCNN4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [55]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [56]
Charybdotoxin DMKN345 Scorpion envenoming syndrome 8D43 Approved [57]
Clotrimazole DMMFCIH Cutaneous candidiasis 1F23.14 Approved [11]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [58]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [59]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [60]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [61]
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [62]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [10]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [64]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [65]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [66]
Estrone DM5T6US Acne vulgaris ED80 Approved [67]
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [68]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [69]
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [70]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [71]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [72]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Arylamine N-acetyltransferase 2 (NAT2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [73]
Hydralazine DMU8JGH Chronic heart failure BD1Z Approved [74]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [75]
Sulfamethoxazole DMB08GE Acute otitis media AB00 Approved [76]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [77]
Quercetin DM3NC4M Obesity 5B81 Approved [78]
Testosterone DM7HUNW Hot flushes GA30 Approved [79]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [80]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [81]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [82]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcium-activated potassium channel (KCN) TTMNI76 NOUNIPROTAC Activator [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [3]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [4]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [5]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [5]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [6]
Cytochrome P450 102A1 (cyp102) DE4OGUF CPXB_BACMB Substrate [7] , [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Arylamine N-acetyltransferase 2 (NAT2) OTBPDQOY ARY2_HUMAN Regulation of Drug Effects [9]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [10]
Intermediate conductance calcium-activated potassium channel protein 4 (KCNN4) OTQKQ346 KCNN4_HUMAN Gene/Protein Processing [11]
Xanthine dehydrogenase/oxidase OTT40HOD XDH_HUMAN Regulation of Drug Effects [9]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2322).
2 Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6.
3 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
4 Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
5 Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80.
6 Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics. 1998 Oct;8(5):375-82.
7 Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
8 The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
9 Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther. 2003 Nov;74(5):468-74. doi: 10.1016/j.clpt.2003.07.001.
10 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
11 Functional and molecular identification of intermediate-conductance Ca(2+)-activated K(+) channels in breast cancer cells: association with cell cycle progression. Am J Physiol Cell Physiol. 2004 Jul;287(1):C125-34. doi: 10.1152/ajpcell.00488.2003. Epub 2004 Feb 25.
12 Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8.
13 Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
14 Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
25 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
26 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
27 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
28 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
29 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
30 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
31 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
32 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
33 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
34 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
35 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
36 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
37 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
38 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
39 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
40 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
41 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
42 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
43 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
44 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
45 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
46 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
47 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
48 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
49 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
50 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
51 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
52 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
53 Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
54 acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
55 Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
56 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
57 4-Chlorobenzo[F]isoquinoline (CBIQ), a novel activator of CFTR and DeltaF508 CFTR. Eur J Pharmacol. 2005 Jun 1;516(2):118-24. doi: 10.1016/j.ejphar.2005.04.037.
58 Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells. Clin Cancer Res. 2007 Sep 1;13(17):5219-25. doi: 10.1158/1078-0432.CCR-07-0816.
59 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
60 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
61 Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell. 2004 Mar;15(3):1262-72. doi: 10.1091/mbc.e03-06-0360. Epub 2003 Dec 29.
62 A novel long noncoding RNA AK001796 acts as an oncogene and is involved in cell growth inhibition by resveratrol in lung cancer. Toxicol Appl Pharmacol. 2015 Jun 1;285(2):79-88.
63 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
64 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
65 Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
66 Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
67 In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
68 Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
69 Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
70 Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
71 Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
72 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
73 Interindividual variability in 5-Fluorouracil metabolism and procainamide N-acetylation in human liver cytosol. Biol Pharm Bull. 2005 Jun;28(6):1071-4. doi: 10.1248/bpb.28.1071.
74 Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem Pharmacol. 2005 Jan 15;69(2):347-59. doi: 10.1016/j.bcp.2004.09.014. Epub 2004 Nov 24.
75 Association analysis of N-acetyl transferase-2 polymorphisms with aspirin intolerance among asthmatics. Pharmacogenomics. 2010 Jul;11(7):951-8. doi: 10.2217/pgs.10.65.
76 Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity. Pharmacogenomics J. 2007 Apr;7(2):144-52. doi: 10.1038/sj.tpj.6500407. Epub 2006 Jul 18.
77 The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases in human lens epithelial cells: inactivation by cellular oxidants and UVB-induced oxidative stress. Mol Pharmacol. 2005 Apr;67(4):1299-306.
78 Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. Clin Exp Pharmacol Physiol. 2009 Aug;36(8):828-33.
79 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
80 Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
81 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
82 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.